Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2 Active not recruiting 15 enrolled Memorial Sloan Kettering Cancer Center

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.

Timeline

Start: 2021-10-08
Primary completion: 2026-10-08
Completion: 2026-10-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CANAGLIFLOZIN ANHYDROUS	Small molecule	300 mg	—
Background	Alpelisib	Small molecule	300 mg	Oral
Background	Fulvestrant	Small molecule	500 mg	Intramuscular

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Summary

Timeline

Drugs

Indications